Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Baumgart DC, Sandborn WJ.

Lancet. 2007 May 12;369(9573):1641-57. Review.

PMID:
17499606
2.

[Therapy of chronic inflammatory bowel diseases].

Beglinger C.

Ther Umsch. 1997 Nov;54(11):649-53. Review. German.

PMID:
9454368
3.

Ulcerative colitis.

Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ.

Lancet. 2012 Nov 3;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0. Review.

4.

Advances in biologic therapy for ulcerative colitis and Crohn's disease.

D'Haens G, Daperno M.

Curr Gastroenterol Rep. 2006 Dec;8(6):506-12. Review.

PMID:
17105690
5.

[5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].

Moum B.

Tidsskr Nor Laegeforen. 2003 Sep 25;123(18):2565-7. Review. Norwegian.

PMID:
14714043
6.

Conventional medical management of inflammatory bowel disease.

Burger D, Travis S.

Gastroenterology. 2011 May;140(6):1827-1837.e2. doi: 10.1053/j.gastro.2011.02.045. Review.

PMID:
21530749
8.

Biologic therapy for inflammatory bowel disease.

Ardizzone S, Bianchi Porro G.

Drugs. 2005;65(16):2253-86. Review.

PMID:
16266194
9.

What's new: innovative concepts in inflammatory bowel disease.

Sandborn WJ.

Colorectal Dis. 2006 May;8 Suppl 1:3-9. Review.

PMID:
16594957
10.

Advances in therapeutic approaches to ulcerative colitis and Crohn's disease.

Travis S.

Curr Gastroenterol Rep. 2005 Dec;7(6):475-84. Review.

PMID:
16313878
11.

Controversies with aminosalicylates in inflammatory bowel disease.

Lim WC, Hanauer SB.

Rev Gastroenterol Disord. 2004 Summer;4(3):104-17. Review.

PMID:
15359211
12.

Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations.

Foster RA, Zander DS, Mergo PJ, Valentine JF.

Inflamm Bowel Dis. 2003 Sep;9(5):308-15.

PMID:
14555914
13.

Mesalamine for inflammatory bowel disease: recent reappraisals.

Actis GC, Pazienza P, Rosina F.

Inflamm Allergy Drug Targets. 2008 Mar;7(1):1-5. Review.

PMID:
18473894
14.

Management of inflammatory bowel disease.

Botoman VA, Bonner GF, Botoman DA.

Am Fam Physician. 1998 Jan 1;57(1):57-68, 71-2. Review.

15.
16.

Mesalazine-induced psoriasis in patients with inflammatory bowel diseases.

Di Cesare A, Fidanza R, Riitano A, Fargnoli MC, Peris K.

Eur J Dermatol. 2011 Sep-Oct;21(5):784-5. doi: 10.1684/ejd.2011.1438. No abstract available.

PMID:
21697068
17.

Pulmonary complications in patients with inflammatory bowel disease.

Kuzela L, Vavrecka A, Prikazska M, Drugda B, Hronec J, Senkova A, Drugdova M, Oltman M, Novotna T, Brezina M, Kratky A, Kristufek P.

Hepatogastroenterology. 1999 May-Jun;46(27):1714-9.

PMID:
10430329
18.

Inflammatory bowel disease and lupus: a systematic review of the literature.

Katsanos KH, Voulgari PV, Tsianos EV.

J Crohns Colitis. 2012 Aug;6(7):735-42. doi: 10.1016/j.crohns.2012.03.005. Review.

19.

Mesalazine for the treatment of inflammatory bowel disease.

Criscuoli V, Modesto I, Orlando A, Cottone M.

Expert Opin Pharmacother. 2013 Aug;14(12):1669-78. doi: 10.1517/14656566.2013.808622. Review.

PMID:
23767798
20.

Encapsulated mesalamine granules (Apriso) for ulcerative colitis.

[No authors listed]

Med Lett Drugs Ther. 2009 May 18;51(1312):38-9. Review.

PMID:
19448588
Items per page

Supplemental Content

Support Center